Thiago Carvalho @cyrilpedia@qoto.org

I'd keep a hardcopy (not just an electronic backup) of all important protocols.
"An electronic lab notebook (ELN) is a software tool for documenting laboratory experiments, research data, and processes. ELNs are set to replace paper lab notebooks as part of the ongoing digital transformation"
https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1012170

'Researchers and activists in the trenches of the long fight against H.I.V. got a rare piece of exciting news this week: Results from a large clinical trial in Africa showed that a twice-yearly injection of a new antiviral drug gave young women total protection from the virus.'
https://www.nytimes.com/2024/06/21/health/lenacapavir-hiv-prevention-africa.html

"Strange though it may sound, the custom of telling the bees about a death in the household has been going on for centuries. It’s been recorded throughout the United Kingdom, as well as parts of France, Germany, Switzerland, and the Netherlands. Beekeepers in parts of New England still keep their hives abreast of certain events, particularly a passing."
https://www.atlasobscura.com/articles/telling-the-bees-death

'Clinical data supported a delayed onset of cognitive impairment in persons who were heterozygous for the APOE3Ch variant in a kindred with a high prevalence of autosomal dominant Alzheimer’s disease.'
https://www.nejm.org/doi/full/10.1056/NEJMoa2308583

'How can we make sense of the fact that animal studies and early clinical trials seem to show promise, yet there is very limited official approval for these therapies? There are 2 possible explanations: One scenario is that the strict requirements of RCTs and regulatory approval are causing many potentially valuable treatments to be left behind. The other scenario is that both animal studies and early clinical trials may have limitations in their design, such as a lack of proper randomization and blinding, which affects their internal validity'

https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002667#sec027

'David Rind, chief medical officer of the Institute for Clinical and Economic Review, an influential non-profit that assesses drug prices, wrote last month that it came with “an enormous price tag” despite failing its primary endpoint as measured by a motor function test.'

https://www.ft.com/content/d5a1f476-56e9-42c9-b029-cde1e11fa89e